Advisory Committee on Immunization Practices: Meeting, 4513-4514 [E7-1490]
Download as PDF
4513
Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form
Respondents
Web-based survey on CVH Toolkit ..
State Heart Disease and Stroke
Programs.
Dated: January 25, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–1489 Filed 1–30–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Cooperative
Agreement for Enhancing Public
Health Practice Related to Birth
Defects and Developmental
Disabilities, Request for Application
(RFA) DD07–002 and Cooperative
Agreement for a National Research
and Training Organization for People
With Developmental and Other
Disabilities, RFA DD07–003
mstockstill on PROD1PC62 with NOTICES
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned SEP:
Time and Date: 1 p.m.–4 p.m., March 19,
2007 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to RFA DD07–002, ‘‘Cooperative
Agreement for Enhancing Public Health
Practice Related to Birth Defects and
Developmental Disabilities,’’ and RFA DD07–
003, ‘‘Cooperative Agreement for a National
Research and Training Organization for
People with Developmental and other
Disabilities.’’
Contact Person for More Information:
Juliana Cyril, PhD, Associate Director for
Policy and Peer Review, Centers for Disease
Control and Prevention, 1600 Clifton Road,
NE., Mailstop D72, Atlanta, GA 30333,
Telephone 404.639.4639.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
VerDate Aug<31>2005
15:08 Jan 30, 2007
Jkt 211001
51
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–1501 Filed 1–30–07; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Task Force on Fetal Alcohol
Syndrome and Fetal Alcohol Effect
(NTFFASFAE): Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned Federal advisory
committee.
Times and Dates: 8:30 a.m.–4:30 p.m.,
February 28, 2007. 8:30 a.m.–1 p.m., March
1, 2007.
Place: SpringHill Suites Atlanta Buckhead,
3459 Buckhead Loop, NE., Atlanta, Georgia
30326, telephone 404/844–4800, fax 404/
844–4801.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 80 people.
Purpose: The Secretary is authorized by the
Public Health Service Act, Section 399G, (42
U.S.C. 280f, as added by Pub. L. 105–392) to
establish a National Task Force on Fetal
Alcohol Syndrome and Fetal Alcohol Effect
to: (1) foster coordination among all
governmental agencies, academic bodies and
community groups that conduct or support
Fetal Alcohol Syndrome (FAS) and Fetal
Alcohol Effect (FAE) research, programs and
surveillance; and (2) to otherwise meet the
general needs of populations actually or
potentially impacted by FAS and FAE.
Matters to Be Discussed: Agenda items
include: Presentation of draft report on
evidence-based fetal alcohol spectrum
disorders (FASD) community-based
prevention strategies with deliberations by
the Task Force; presentation on U.S.
Preventive Services Task Force report on
alcohol use screening and behavioral
counseling interventions; report on work of
Post-exposure working group regarding
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden
per response
(in hrs.)
1
Total burden
(in hours)
0.5
25.5
recommendations for future directions in
FASD policy and research; updates from the
Interagency Coordinating Committee on FAS,
the CDC and other Federal agencies, and
liaison representatives; and scheduling of the
next meeting.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Mary
Kate Weber, M.P.H., Designated Federal
Official, National Center on Birth Defects and
Developmental Disabilities, CDC, 1600
Clifton Road, NE., (E–86), Atlanta, Georgia
30333, telephone 404/498–3926, fax 404/
498–3550.
The Acting Director, Management Analysis
and Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and ATSDR.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–1493 Filed 1–30–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices: Meeting
Correction: This notice was published
in the Federal Register on December 8,
2006, Volume 71, Number 236, page
71175–71176. The matters to be
discussed have changed.
Matters To Be Discussed: The agenda
will include discussions on influenza
vaccine; immunization safety; update on
use of rotavirus vaccine; update on use
of HPV vaccine; update on use of herpes
zoster (shingles) vaccine; vaccine
supply; Japanese encephalitis and other
flavivirus vaccines (e.g., yellow fever
vaccine); diphtheria, tetanus, pertussis,
polio, Haemophilus B [Hib]
combination vaccine (Pentacel);
evidence-based recommendations; and
agency updates. Vaccine for Children
votes will be on hepatitis A post
exposure prophylaxis, influenza and
Pentacel. Agenda items are subject to
change as priorities dictate.
E:\FR\FM\31JAN1.SGM
31JAN1
4514
Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices
For Further Information Contact:
Demetria Gardner, Immunization
Services Division, National Center for
Immunization and Respiratory Diseases,
CDC, 1600 Clifton Road, NE., (E–05),
Atlanta, Georgia 30333, telephone 404/
639–8836, fax 404/639–6258.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the CDC
and ATSDR.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–1490 Filed 1–30–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on PROD1PC62 with NOTICES
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 71 FR 69211, dated
November 30, 2006) is amended to
reflect the establishment of the
Extramural Research Program Office
within the National Center for Injury
Prevention and Control, coordinating
Center for Environmental Health and
Injury Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows: After the functional statement
for the Office of Communication
Resources (CTC14), Office of the
Director (CTC1), National Center for
Injury Prevention and Control (CTC),
insert the following:
Extramural Research Program Office
(CTC16). The Extramural Research
Program Office (ERPO) plans, develops,
coordinates, and evaluates extramural
research activities in cooperation with
centers, divisions, and offices within the
Coordinating Center for Environmental
Health and Injury Prevention. In
carrying out its mission, the ERPO: (1)
Directs the Extramural research program
by planning, coordinating, developing,
implementing, monitoring, and
evaluating extramural research that is
designed to address center priorities; (2)
VerDate Aug<31>2005
15:08 Jan 30, 2007
Jkt 211001
participates with divisions and offices
within the center to establish research
priorities for the center; (3) provides
scientific leadership in the areas of
extramural research supported by the
center; (4) promotes and prepares
initiatives to stimulate extramural
research in relevant priority areas; (5)
coordinates and conducts in-depth
external peer review and secondary
program relevance review of extramural
research applications by use of
consultant expert panels; (6) makes
recommendations to the center director
on award selections and staff members
serve as the program officials in
conjunction with CDC grants
management and policy officials to
implement and monitor the scientific,
technical, and administrative aspects of
awards; (7) facilitates scientific
collaborations between external and
internal investigators; (8) disseminates
and evaluates extramural research
progress, findings, and impact; and (9)
assists the Office of Chief Science
Officer, CDC, in developing extramural
research policies and oversees the
implementation of those policies within
the center.
Dated: January 9, 2007.
William H. Gimson,
Chief Operating Officer, Centers for Disease
Control and Prevention (CDC).
[FR Doc. 07–417 Filed 1–30–07; 8:45 am]
BILLING CODE 4160–18–M
Food and Drug Administration
[Docket No. 2006N–0136]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Interstate Shellfish Dealers Certificate
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Interstate Shellfish Dealers Certificate’’
has been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 13, 2006 (71
PO 00000
Frm 00038
Fmt 4703
Dated: January 25, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–1549 Filed 1–30–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[FDA 225–07–4300]
Memorandum of Understanding
Between the United States Food and
Drug Administration and the Veterans
Health Administration
AGENCY:
Sfmt 4703
Food and Drug Administration,
HHS.
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
FR 60545), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0021. The
approval expires on January 31, 2010. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.fda.gov/
ohrms/dockets.
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is providing
notice of a memorandum of
understanding (MOU) between FDA and
the Veterans Health Administration.
The purpose of this MOU is to enhance
knowledge and efficiency by providing
for the sharing of information and
expertise related to the review and use
of FDA-regulated drugs, biologics, and
medical devices between the two
agencies. The goals of the collaboration
are to explore ways to: Further enhance
information sharing efforts through
more efficient and robust interagency
activities; promote efficient utilization
of tools and expertise for product risk
identification, validation, and analysis;
and build infrastructure and processes
that meet the common needs for
evaluating the safety, efficacy, and
utilization of drugs, biologics, and
medical devices.
DATES: The agreement became effective
January 23, 2007.
FOR FURTHER INFORMATION CONTACT:
Jeffrey Shuren, Office of Policy (HF–11),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–827–3360.
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 72, Number 20 (Wednesday, January 31, 2007)]
[Notices]
[Pages 4513-4514]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-1490]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices: Meeting
Correction: This notice was published in the Federal Register on
December 8, 2006, Volume 71, Number 236, page 71175-71176. The matters
to be discussed have changed.
Matters To Be Discussed: The agenda will include discussions on
influenza vaccine; immunization safety; update on use of rotavirus
vaccine; update on use of HPV vaccine; update on use of herpes zoster
(shingles) vaccine; vaccine supply; Japanese encephalitis and other
flavivirus vaccines (e.g., yellow fever vaccine); diphtheria, tetanus,
pertussis, polio, Haemophilus B [Hib] combination vaccine
(Pentacel[reg]); evidence-based recommendations; and agency updates.
Vaccine for Children votes will be on hepatitis A post exposure
prophylaxis, influenza and Pentacel. Agenda items are subject to change
as priorities dictate.
[[Page 4514]]
For Further Information Contact: Demetria Gardner, Immunization
Services Division, National Center for Immunization and Respiratory
Diseases, CDC, 1600 Clifton Road, NE., (E-05), Atlanta, Georgia 30333,
telephone 404/639-8836, fax 404/639-6258.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the CDC and ATSDR.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. E7-1490 Filed 1-30-07; 8:45 am]
BILLING CODE 4163-18-P